Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript

Core Insights - Alnylam has pioneered RNAi therapeutics, marking over 20 years of development with significant advancements in delivery mechanisms [1][2] - The company currently has six commercial products, with a focus on expanding into the cardiomyopathy segment of the ATTR market [2] - Alnylam boasts a robust pipeline of approximately 20 medicines in clinical development, leveraging its innovative platform technology [2]